News

September 28, 2011 — A clinical trial by Resverlogix Corp. is evaluating the early effects of a new drug compound in atherosclerotic plaque regression. The study is focused on patients with...

September 15, 2011 – The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular...

September 8, 2011 – A randomized multicenter, open-label study evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months'...

September 8, 2011 – Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the...

September 6, 2011 — The European Society of Cardiology (ESC) released the latest version of its guidelines for managing patients presenting without persistent ST-segment elevation. This version...

August 30, 2011 – Compared with patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence...

August 18, 2011 — The antiplatelet agent prasugrel (trade name Effient), in combination with aspirin, was associated with 26 percent relative risk reduction in cardiovascular death, myocardial...

Aug. 2, 2011 — New York University (NYU) Langone Medical Center has received an $84 million grant from the National Heart, Lung and Blood Institute (NHLBI) to study the comparative effectiveness...

July 21, 2011 – The U.S. Food and Drug Administration (FDA) today approved AstraZeneca’s blood-thinning drug ticagrelor (Brilinta) to reduce cardiovascular death and heart attack in patients with...

July 5, 2011 — Janssen Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for the...
June 30, 2011 — Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. announced today that two additional analyses from phase 3 studies of mipomersen were presented at the 79th European...
June 14, 2011 – New performance measures for adults with coronary artery disease (CAD) and hypertension were released today by the American College of Cardiology Foundation (ACCF), the American Heart...
June 10, 2011 – The U.S. Food and Drug Administration (FDA) announced safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose – 80 milligram (mg) –...
June 3, 2011 – European CE mark approval was granted to expand use of the VerifyNow point-of-care P2Y12 test platelet reactivity test to identify patients who are poor-responders to antiplatelet...

April 22, 2011 – A new study found that coronary artery bypass surgery added to medical therapy for selected chronic heart failure patients offered benefits over medical therapy alone.

April 21, 2011 – A new angiotensin II receptor blocker (ARB) has been approved by the U.S. Food and Drug Administration (FDA) to treat hypertension, or high blood pressure. Edarbi (azilsartan...

April 21, 2011 – Baxter International has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, a specialty pharmaceutical company based in King of Prussia, Penn....

April 7, 2011 – Primary results from the RADAR Phase 2b clinical trial were announced at the American College of Cardiology (ACC) 2011 60th Annual Scientific Session. The trial looked at Regado...

April 7, 2011 – New study results have evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on clopidogrel (Plavix). The results showed that in healthy subjects,...

April 7, 2011 – Data from two phase 3 trials studying a drug for high-cholesterol patients who are on lipid-lowering therapy were presented at American College of Cardiology’s (ACC) 60th Annual...